(Q36673011)

15 August 2017

1 reference

title

Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders (English)

1 reference

15 August 2017

1 reference

Lawrence James Hirsch

series ordinal

3

object named as

Lawrence J Hirsch

1 reference

15 August 2017

Sheetal Malik

1

1 reference

15 August 2017

Hiba Arif

series ordinal

2

1 reference

15 August 2017

language of work or name

1 reference

1 November 2006

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

published in

1 reference

15 August 2017

volume

6

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1609-1627

1 reference

Prevalence of epilepsy in Rochester, Minnesota: 1940-1980.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Cost of epilepsy in the United States: a model based on incidence and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Early identification of refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Clinical aspects and biological bases of drug-resistant epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

The epileptogenic action of Na-folate in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Review of lamotrigine and its clinical applications in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamictal (lamotrigine) monotherapy for typical absence seizures in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Effect of lamotrigine on plasma GABA levels in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Clinical pharmacology of lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

The pharmacokinetics and interactions of new antiepileptic drugs: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Sodium valproate acutely inhibits lamotrigine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Effect of antiepileptic drug comedication on lamotrigine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Oral contraceptives reduce lamotrigine plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine plasma levels reduced by oral contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Influence of cirrhosis on lamotrigine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Population pharmacokinetics of lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Efficacy, tolerability, and kinetics of lamotrigine in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Antiepileptic drugs: a case report in a pregnancy with a neural tube defect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine and the risk of malformations in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Australian pregnancy registry of women taking antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine clearance during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

The impact of pregnancy and childbirth on the metabolism of lamotrigine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Long-term tolerability of lamotrigine: data from a 6-year continuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine for the treatment of epilepsy in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: an open, prospective, long-term study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Low-dose lamotrigine in West syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine for central poststroke pain: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Preventing disturbing migraine aura with lamotrigine: an open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Safety review of adult clinical trial experience with lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Predictors of Lamotrigine-associated rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Potential hepatotoxicity of lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Fatal progressive hepatic necrosis associated with lamotrigine treatment: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Acute hepatitis after lamotrigine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Acute hepatitis associated with lamotrigine and managed with the molecular adsorbents recirculating system (Mars).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine associated with insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Effect of lamotrigine on cognition in children with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

New antiepileptic drugs in children: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Lamotrigine in absence and primary generalized epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Overview of lamotrigine and the new antiepileptic drugs: the challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

Rechallenge with lamotrigine after initial rash

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.11.1609

10.1586/14737175.6.11.1609

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference